TNSN05204A1 - 3-2-phenyl-oxazol-4-ylmethoxy)cyclohexylmethoxy acetic acid derivatives and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis - Google Patents

3-2-phenyl-oxazol-4-ylmethoxy)cyclohexylmethoxy acetic acid derivatives and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis

Info

Publication number
TNSN05204A1
TNSN05204A1 TNP2005000204A TNSN05204A TNSN05204A1 TN SN05204 A1 TNSN05204 A1 TN SN05204A1 TN P2005000204 A TNP2005000204 A TN P2005000204A TN SN05204 A TNSN05204 A TN SN05204A TN SN05204 A1 TNSN05204 A1 TN SN05204A1
Authority
TN
Tunisia
Prior art keywords
acetic acid
acid derivatives
cyclohexylmethoxy
ylmethoxy
oxazol
Prior art date
Application number
TNP2005000204A
Other languages
English (en)
Inventor
Dirk Gretzke
Heiner Glombik
Eugen Falk
Jochen Goerlitzer
Stefanie Keil
Hans-Ludwig Schaefer
Christian Stapper
Wolfgang Wendler
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of TNSN05204A1 publication Critical patent/TNSN05204A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
TNP2005000204A 2003-02-27 2005-08-26 3-2-phenyl-oxazol-4-ylmethoxy)cyclohexylmethoxy acetic acid derivatives and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis TNSN05204A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001579 WO2004076427A1 (de) 2003-02-27 2004-02-19 3-(2-phenyl-oxazol-4- ylmethoxy)-cyclohexylmethoxy -essigsäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (1)

Publication Number Publication Date
TNSN05204A1 true TNSN05204A1 (en) 2007-06-11

Family

ID=32920629

Family Applications (2)

Application Number Title Priority Date Filing Date
TNP2005000204A TNSN05204A1 (en) 2003-02-27 2005-08-26 3-2-phenyl-oxazol-4-ylmethoxy)cyclohexylmethoxy acetic acid derivatives and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis
TNP2005000206A TNSN05206A1 (en) 2003-02-27 2005-08-26 3-methyl-2-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
TNP2005000206A TNSN05206A1 (en) 2003-02-27 2005-08-26 3-methyl-2-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis

Country Status (34)

Country Link
US (5) US7335671B2 (US07259177-20070821-C00136.png)
EP (3) EP1599455B1 (US07259177-20070821-C00136.png)
JP (3) JP2006519193A (US07259177-20070821-C00136.png)
KR (3) KR20050106461A (US07259177-20070821-C00136.png)
CN (3) CN100439347C (US07259177-20070821-C00136.png)
AR (3) AR043432A1 (US07259177-20070821-C00136.png)
AT (3) ATE435217T1 (US07259177-20070821-C00136.png)
AU (3) AU2004215677B2 (US07259177-20070821-C00136.png)
BR (3) BRPI0407758A (US07259177-20070821-C00136.png)
CA (3) CA2517381A1 (US07259177-20070821-C00136.png)
CL (2) CL2004000392A1 (US07259177-20070821-C00136.png)
CO (2) CO5690580A2 (US07259177-20070821-C00136.png)
DE (4) DE10308355A1 (US07259177-20070821-C00136.png)
DK (3) DK1599452T3 (US07259177-20070821-C00136.png)
EC (2) ECSP055985A (US07259177-20070821-C00136.png)
ES (3) ES2326418T3 (US07259177-20070821-C00136.png)
HR (3) HRP20050743A2 (US07259177-20070821-C00136.png)
IL (2) IL170314A (US07259177-20070821-C00136.png)
MA (3) MA27736A1 (US07259177-20070821-C00136.png)
MX (3) MXPA05008995A (US07259177-20070821-C00136.png)
NO (3) NO20054396L (US07259177-20070821-C00136.png)
OA (2) OA13034A (US07259177-20070821-C00136.png)
PA (1) PA8596801A1 (US07259177-20070821-C00136.png)
PE (3) PE20040959A1 (US07259177-20070821-C00136.png)
PL (3) PL378437A1 (US07259177-20070821-C00136.png)
PT (3) PT1599452E (US07259177-20070821-C00136.png)
RS (1) RS20050594A (US07259177-20070821-C00136.png)
RU (3) RU2005129992A (US07259177-20070821-C00136.png)
SA (1) SA04250153A (US07259177-20070821-C00136.png)
TN (2) TNSN05204A1 (US07259177-20070821-C00136.png)
TW (3) TW200508210A (US07259177-20070821-C00136.png)
UY (2) UY28210A1 (US07259177-20070821-C00136.png)
WO (3) WO2004076427A1 (US07259177-20070821-C00136.png)
ZA (2) ZA200505765B (US07259177-20070821-C00136.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
EP1931337B1 (en) 2005-09-29 2013-10-23 Sanofi Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
US8128969B2 (en) 2006-08-10 2012-03-06 Mimozax Co., Ltd. Hypoglycemic composition containing acacia bark derivative
JP5340287B2 (ja) 2007-08-16 2013-11-13 ソルヴェイ(ソシエテ アノニム) 4−フルオロ置換3−オキソ−アルカン酸のエステル類の調製方法
EP2246343B1 (en) 2008-02-29 2016-05-18 Nissan Chemical Industries, Ltd. Process for production of thiophene compound and intermediate thereof
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
CN116184784A (zh) 2017-12-13 2023-05-30 佳能株式会社 盒与图像形成装置
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) * 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
AU727775B2 (en) 1996-01-17 2000-12-21 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
DK0944648T3 (da) 1996-08-30 2007-07-02 Novo Nordisk As GLP-1 derivater
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
ES2199366T3 (es) 1996-12-31 2004-02-16 Dr. Reddy's Laboratories Ltd. Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas.
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
BR9810592A (pt) 1997-07-16 2000-09-12 Novo Nordisk As Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
WO1999046232A1 (fr) * 1998-03-10 1999-09-16 Ono Pharmaceutical Co., Ltd. Derives d'acide carboxylique et medicaments contenant ces derives comme principe actif
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
WO2000012491A1 (fr) * 1998-08-27 2000-03-09 Ono Pharmaceutical Co., Ltd. Derives d'acide carboxylique et medicaments dont ils sont le principe actif
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6908926B1 (en) * 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
EP1177187B1 (en) 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
RU2278860C2 (ru) * 1999-04-28 2006-06-27 Санофи-Авентис Дойчланд Гмбх Производные триарил-содержащих кислот в качестве лигандов рецепторов ппар
CA2371271A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
ES2265952T3 (es) 1999-06-18 2007-03-01 MERCK & CO., INC. Derivados de ariltiazolidindiona y ariloxazolidindiona.
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
ES2203498T3 (es) 1999-07-29 2004-04-16 Eli Lilly And Company Benzofurilpiperazinas: agonistas de receptor 5-ht2c de la serotonina.
CA2383781A1 (en) * 1999-09-01 2001-03-08 Aventis Pharma Deutschland Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
WO2001040171A1 (en) 1999-12-03 2001-06-07 Astrazeneca Ab Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
IL151368A0 (en) 2000-03-31 2003-04-10 Probiodrug Ag Use of a dipeptidyl peptidase iv enzyme activity effector for the production of pharmaceutical compositions
MXPA02010545A (es) 2000-04-25 2004-05-14 Kyorin Seiyaku Kk Cristal estable novedoso de derivado de tiazolidinediona y proceso para producir el mismo.
CN1430603A (zh) 2000-04-28 2003-07-16 旭化成株式会社 新型双环化合物
AU5959201A (en) 2000-05-11 2001-11-20 Bristol Myers Squibb Co Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
EE200200634A (et) * 2000-06-09 2004-04-15 Aventis Pharma Deutschland Gmbh Atsüülfenüülkarbamiidi derivaadid, nende saamine ja kasutamine veresuhkrut alandava ravimi valmistamiseks ning neid sisaldav ravim
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
IL154110A0 (en) * 2000-08-23 2003-07-31 Lilly Co Eli Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
EP1313715B1 (en) 2000-08-23 2007-08-01 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
AU2002222573A1 (en) 2000-12-05 2002-06-18 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
PT1345895E (pt) 2000-12-21 2007-02-28 Sanofi Aventis Deutschland Novas difenilazetidinonas, processo para a sua preparação, fármacos contendo estes compostos e sua utilização para o tratamento de distúrbios do metabolismo lipídico
US7220864B2 (en) * 2000-12-25 2007-05-22 Ono Pharmaceutical Co., Ltd. Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient
BR0207285A (pt) * 2001-02-15 2004-02-10 Pfizer Producs Inc Agonistas de ppar
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
BR0210167A (pt) * 2001-06-07 2004-04-06 Lilly Co Eli Composto, composição farmacêutica, métodos para modular um receptor ativado com proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição e para abaixar a glicose no sangue, e, uso de um composto
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003004458A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab New compounds
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
OA12656A (en) 2001-08-31 2006-06-19 Aventis Pharma Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators.
US6984661B2 (en) 2002-02-05 2006-01-10 Eli Lilly And Company Urea linker derivatives for use as PPAR modulators
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
AU2003259131A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
UY28210A1 (es) 2004-09-30
HRP20050744A2 (en) 2006-09-30
EP1599453B1 (de) 2009-05-06
CN100439345C (zh) 2008-12-03
SA04250153A (ar) 2005-12-03
AR043433A1 (es) 2005-07-27
DK1599453T3 (da) 2009-08-24
AU2004215677B2 (en) 2010-01-07
NO20054398D0 (no) 2005-09-22
ES2326418T3 (es) 2009-10-09
WO2004076428A1 (de) 2004-09-10
MXPA05008988A (es) 2005-10-18
CL2004000391A1 (es) 2005-01-07
CN1753879A (zh) 2006-03-29
US7259177B2 (en) 2007-08-21
AU2004215673A1 (en) 2004-09-10
CN100439347C (zh) 2008-12-03
PT1599453E (pt) 2009-07-14
AU2004215672B2 (en) 2010-01-07
US7365084B2 (en) 2008-04-29
MXPA05008951A (es) 2005-11-04
EP1599453A1 (de) 2005-11-30
MXPA05008995A (es) 2005-10-18
RU2005129992A (ru) 2006-02-10
BRPI0407758A (pt) 2006-02-14
ATE435217T1 (de) 2009-07-15
EP1599455A1 (de) 2005-11-30
CO5690578A2 (es) 2006-10-31
OA13035A (en) 2006-11-10
IL170314A (en) 2010-11-30
RU2005130002A (ru) 2006-01-27
PT1599455E (pt) 2009-09-29
KR20050106461A (ko) 2005-11-09
ECSP055985A (es) 2006-01-16
KR20050106462A (ko) 2005-11-09
DK1599452T3 (da) 2007-10-01
DE502004009453D1 (de) 2009-06-18
CN100398526C (zh) 2008-07-02
NO20054396D0 (no) 2005-09-22
EP1599452A1 (de) 2005-11-30
JP2006519199A (ja) 2006-08-24
EP1599452B1 (de) 2007-06-20
PT1599452E (pt) 2007-09-12
NO20054408D0 (no) 2005-09-22
AU2004215673B2 (en) 2009-10-01
DE10308355A1 (de) 2004-12-23
US20040209920A1 (en) 2004-10-21
PE20050292A1 (es) 2005-05-24
ES2287700T3 (es) 2007-12-16
RU2005129995A (ru) 2006-01-27
NO20054398L (no) 2005-11-02
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
BRPI0407907A (pt) 2006-02-14
CN1756748A (zh) 2006-04-05
US20080015238A1 (en) 2008-01-17
MA27736A1 (fr) 2006-02-01
BRPI0407814A (pt) 2006-02-14
KR20050105492A (ko) 2005-11-04
JP2006519194A (ja) 2006-08-24
US7335671B2 (en) 2008-02-26
MA27737A1 (fr) 2006-02-01
EP1599455B1 (de) 2009-07-01
TW200508210A (en) 2005-03-01
ATE430738T1 (de) 2009-05-15
US20080167354A1 (en) 2008-07-10
PL378130A1 (pl) 2006-03-06
CA2517386A1 (en) 2004-09-10
OA13034A (en) 2006-11-10
HRP20050742A2 (en) 2006-09-30
WO2004076426A1 (de) 2004-09-10
RS20050594A (en) 2007-12-31
CO5690580A2 (es) 2006-10-31
PL377735A1 (pl) 2006-02-20
ATE365159T1 (de) 2007-07-15
CA2517381A1 (en) 2004-09-10
ECSP055986A (es) 2006-01-16
NO20054396L (no) 2005-11-11
JP2006519193A (ja) 2006-08-24
TW200510352A (en) 2005-03-16
US20050101637A1 (en) 2005-05-12
AU2004215677A1 (en) 2004-09-10
UY28209A1 (es) 2004-09-30
ZA200505765B (en) 2006-05-31
US20050215596A1 (en) 2005-09-29
AR043432A1 (es) 2005-07-27
CL2004000392A1 (es) 2005-04-22
ZA200505768B (en) 2005-11-23
PE20040959A1 (es) 2005-01-17
CA2516620A1 (en) 2004-09-10
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
AR043427A1 (es) 2005-07-27
PL378437A1 (pl) 2006-04-03
ES2329366T3 (es) 2009-11-25
TNSN05206A1 (en) 2007-06-11
DE502004009690D1 (de) 2009-08-13
AU2004215672A1 (en) 2004-09-10
MA27742A1 (fr) 2006-02-01
US7872034B2 (en) 2011-01-18
PE20050293A1 (es) 2005-05-24
TW200500349A (en) 2005-01-01
CN1753881A (zh) 2006-03-29
DE502004004139D1 (de) 2007-08-02
WO2004076427A1 (de) 2004-09-10
DK1599455T3 (da) 2009-11-09

Similar Documents

Publication Publication Date Title
TNSN05204A1 (en) 3-2-phenyl-oxazol-4-ylmethoxy)cyclohexylmethoxy acetic acid derivatives and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis
RS20050019A (en) Heterocyclically substituted benzoylureas,method for their production and their use as medicaments
IL173203A0 (en) Novel cyano thiazolides, methods for the production thereof, and use thereof as a medicament
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
MX2009002920A (es) Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos.
MX2007006311A (es) Acidos hidroxibifenilcarboxilicos y derivados, metodo para producirlos y su uso.
WO2004113270A3 (en) Propionic acid derivatives useful in the treatment of lipid disorders
RS16704A (en) Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
MY148096A (en) 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
WO2007106469A3 (en) Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
NO20054382L (no) Diarylsykloalkylderivater, deres fremstilling og deres anvendelse som legemiddel
IL176914A0 (en) Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
MXPA05010128A (es) Nueva difenilazetidinona con caracteristicas fisiologicas mejoradas, correspondiente metodo de produccion, medicamentos que contienen dicho compuesto y su uso.
IL176915A0 (en) Cycloalkyl substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
WO2003006443A3 (de) 2-`4-(naphtalin-2yl)-thiazol-2-ylaminocarbonyl benzoesäure und 2-`4-(naphtalin-2yl)-pyrimidin-2-ylaminocarbonyl benzoesäure und andere verbindungen als telomerase-hemmer zur anwendung in der tumortherapie
NO20054418L (no) Substituert benzoylureidopyridylpiperidin- og -pyrrolidinkarboksylsyrederivater, deres fremstilling og anvendelse
TNSN06233A1 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
MA27649A1 (fr) Derives d'acylphenyluree substitues par carbonylamino, methode de production et d'utilisation de ceux-ci.
MXPA05009054A (es) Derivados de arilcicloalquilo con cadenas laterales ramificadas en calidad de moduladores de receptores ppar, metodo para su produccion y su uso como medicamentos.
MXPA05008990A (es) Derivados de acido alcanoico sustituido con cicloalquilo, metodos para su produccion y su uso como medicamentos.
MXPA05008331A (es) Derivados de 3-(benzoilureido)-tiofeno sustituido, metodo para su produccion y uso de los mismos.
TNSN05205A1 (en) Cycloalkyl derivatives comprising bioisosteric carboxylic acid groups, method for the production thereof, and use thereof as a medicament
MX2007010841A (es) 8-pirrolidinobenzimidazoles biciclicos sustituidos, un metodo para su produccion y su uso como medicamentos.
WO2004033416A3 (de) Carboxyalkoxy-substituierte acyl-carboxyphenyl-harnstoffderivate, verfahren zu ihre herstellung und ihre verwendung als arzneimittel